Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

The P2Y 12 receptor is a key player in platelet activation and represents an effective
pharmacological target for the inhibition of platelet aggregation and prevention of …

Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute
coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death …

Background—In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on
Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce …

Abstract Background Oral P2Y12 receptor antagonists exhibit delayed onset of platelet
inhibition in patients with acute myocardial infarction (AMI). Selatogrel is a potent, highly …

Aims Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced
platelet response to clopidogrel compared with patients without DM. Prasugrel, a more …

Background There is wide variability in the reported incidence of perioperative
thromboembolic (0–14%) and hemorrhagic (0–11%) complications after Pipeline …

The two most widely used antiplatelet drugs in the world are aspirin and clopidogrel.
However, some patients on aspirin and/or clopidogrel therapy do not respond appropriately …

OBJECTIVES: We aimed to investigate the relationship between platelet microRNA (miR-
223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart …